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ABSTRACT 
 
Background: Iron and docosahexaenoic acid (DHA) are important nutrients for 
brain development; however, it has been shown that when status of both 
nutrients is low, DHA supplementation may actually impair cognitive outcomes. 
 
Objective: To determine if DHA status interacts with iron deficiency (ID) during 
pregnancy and influences cognitive function of the offspring. We studied a 
sample of convenience (n=271, women given a placebo oil or 600 mg/d DHA 
during the last two trimesters of pregnancy). Maternal and infant nutritional status 
with respect to iron and DHA were also assessed. 
 
Design: Maternal blood samples were obtained postpartum to assess for iron 
and DHA status while offspring blood samples were measured through cord 
blood at delivery and also at 4 months. In the maternal infant pairs, we identified 
ID by enzyme-linked immunosorbent assay (ELISA) and determined DHA 
status (erythrocyte weight %) by gas liquid chromatography. ID was analyzed by 
several markers including serum transferrin receptor (sTfR), serum ferritin (SF) 
and body iron (BI). DHA status was defined as low or normal by a median split. 
We measured offspring cognitive performance on the Bayley Scales of Infant 
Development Index II (BSID-II) Mental Developmental Index (MDI) and 
Psychomotor Developmental Index (PDI) at 18 months (n=191). Analysis of 
variance (ANOVA) was used to examine the relationship between maternal iron 
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and DHA status with cognitive performance; covariates were taken into account. 
A priori comparisons of ID-low DHA and ID-normal DHA were conducted. 
Student’s t-tests assuming equal variance and simple correlations were also 
used.  
 
Results: ID was observed in 18% of the maternal population at delivery, 0% of 
the infant population at delivery, and 2% of the infant population at 4 months of 
age based on BI concentration. The only significant correlations seen between 
individual maternal iron and BSID outcomes were with SF and PDI and first and 
third Hb measurements and MDI. A significant negative correlation was observed 
between RBC-phospholipid-DHA (RBC-PL-DHA) and PDI. ANOVAs and 
ANOVAs with covariates taken into account showed no significant results. A 
priori comparisons resulted in the observation of MDI scores of (mean ± SD) of 
90.1±7.3 and 98.2±9.4, t=2.07, p=0.054 among the mothers with ID, low DHA 
and ID, normal DHA.  
 
Conclusions: Our population has iron status similar to that of other pregnant 
American women based on BI. Our results differ from recent findings examining 
the potential interaction between iron and DHA status on infant cognitive 
outcomes. Although our sample size of ID women was limited, we detected a 
trend suggesting that higher DHA status in ID pregnancy may protect against the 
adverse effects of maternal ID on the BSID-II MDI.  
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Chapter 1 
INTRODUCTION 
Iron and docosahexaenoic acid (DHA) are two nutrients known to be 
influential in the development of the central nervous system. Iron deficiency (ID) 
has been associated with negative developmental outcomes, while DHA is a 
nutrient of interest being studied in relation to improved developmental outcomes.  
Research examining both iron and DHA in relation to development is 
limited, and there are differences in results in the literature. Several attempts 
have been made to establish an association between maternal iron and DHA 
status in conjunction with infants’ cognitive performances. These studies have 
not resulted in significant findings and have led researchers to suggest larger 
scale studies are needed (1). Recently, a negative effect of DHA 
supplementation on working memory was reported in children with anemia 
(though not necessarily iron deficiency anemia [IDA]) compared to iron deficient 
(ID) children without anemia, while ID females had negative outcomes on long 
term memory (2). Similar findings were reported in the male rat model when 
repletion of either DHA/EPA or iron was given to rats presenting with a dual 
deficiency (3).   
Statement of Purpose 
The purpose of this study is to assess the relationship between maternal 
DHA and iron status in conjunction with infants’ cognitive outcomes at 18 months. 
The cohort study were children of women who were randomly assigned to DHA 
during the last half of pregnancy in the KU DHA Outcomes Study (KUDOS). 
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Research Questions 
Primary Research Questions 
1. What is the nutritional status, pertaining to iron and DHA, of mother 
and child?  
2. Does maternal iron or DHA status predict Bayley Scales of Infant 
Development (BSID-II) Mental Developmental Index (MDI) and 
Psychomotor Developmental Index (PDI) scores at 18 months of age?  
Secondary Research Question 
1. Do maternal iron and DHA status interact to influence early 
developmental outcomes (BSID-II MDI and PDI) of children at 18 
months of age? 
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Chapter 2 
LITERATURE REVIEW 
 Iron and DHA have been studied independently in relation to early 
developmental outcomes including motor, language and cognitive development. 
However, the potential relationship between the two in relation to developmental 
outcomes has been minimally studied. While it might be presumed that these 
nutrients would both have positive effects on development, recent reports show a 
negative effect of repletion with DHA when iron stores are low; two recent studies 
found negative cognitive outcomes in rats and children with deficient iron-stores 
and supplemented with DHA (1-3).  
Iron  
ID is the most common micronutrient deficiency in the world (4). The most 
recent statistic from a World Health Organization (WHO) report on the presence 
of anemia claims an estimated two billion people worldwide are affected by ID (5). 
Analysis of worldwide data found children and pregnant women to have the 
highest risk for anemia, with one in four affected (6). It is estimated that 9-11% of 
non-pregnant, US women of reproductive age has ID, with IDA prevalent in 2-5% 
of this same population (7). 
 ID adversely affects health and development with and without IDA, and 
therefore IDA and ID are distinguished in discussing the literature (5). I will use 
the definitions discussed below when referring to ID and anemia. ID is present 
when iron stores are below the required amount to support normal physiological 
function of bodily tissues (5). There are various measurements to determine this, 
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with serum ferritin (SF) being the preferred method for the detection of depleted 
iron stores (8). However, SF decreases late in pregnancy and is not a preferred 
measurement during this timeframe (8). SF concentrations of <15 µg/l for 
females of reproductive age and <10 µg/l for children <6 years of age are defined 
as levels implying that iron stores are depleted (8-10). However, SF values 
reflect a less sensitive measurement of iron status during states of inflammation 
such as pregnancy (10). Serum transferrin receptor (sTfR) is a relatively new 
addition to testing for ID. An advantage of this measurement is that it does not 
vary with pregnancy (5, 8). sTfR increases as iron stores are depleted.  (8). 
There is not a universal reference value for sTfR, however, individuals with a 
plasma or serum value ≥8.4 mg/dL are typically considered ID. Body iron (BI) 
concentration is an additional, also relatively new measurement of iron status 
that is determined from SF and sTfR concentrations (11). A BI concentration 
<0mg/kg indicates the absence of iron stores and is another indicator of ID (11).   
Anemia is defined as a hemoglobin concentration less than the threshold 
necessary to adequately transport oxygen that is due to ID (6). Thresholds are 
described by age and sex, with a separate threshold for pregnant women 
compared to non-pregnant women (5). The WHO considers women older than 
age 15 who are not pregnant to be anemic if their blood hemoglobin 
concentration is less than 12 g/dL (8). Pregnant women are considered anemic 
with blood hemoglobin levels less than 11 g/dL (8). Severe anemia is defined as 
blood hemoglobin levels less than 7 g/dL (8).  If the anemia is due to iron 
deficiency, it is termed IDA. 
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 The prevalence of ID can be attributed to inadequate intake of dietary iron 
in order to meet needs for growth and development, and IDA occurs when ID is 
so severe that the body cannot maintain adequate hemoglobin in the blood.  
Aside from fortified sources and supplementation, dietary iron sources consist of 
heme iron and non-heme iron. Dietary heme iron is found in some animal foods 
and is absorbed more efficiently by the body than non-heme iron, a derivative of 
plant sources (12). Heme iron in meats generally comprises 30-70% of iron 
content, with 15-35% of the heme iron absorbed by the body (12). It is estimated 
that less than 10% of non-heme iron is absorbed from plant based foods (12). 
Iron requirements are ultimately increased in pregnancy due to fetal uptake (13). 
Iron needs are the lowest in the first trimester due to the absence of menstruation, 
however, iron needs increase in the second and third trimesters due to 
increasing fetal absorption of iron (13). Iron requirements are highest in the third 
trimester of pregnancy, which is also the period of maximal fetal iron uptake (13, 
14).  
DHA 
DHA is a long-chain omega-3 polyunsaturated fatty acid (LC-PUFA) that is 
transferred from mother to the fetus in utero and to the infant fed human milk. 
Fetal iron accumulation in the brain and retina is highest in the third trimester, 
(15), however, maternal intake earlier in pregnancy likely contributes to fetal 
uptake into other tissues (e.g., adipose tissue) that may provide DHA for the 
brain and retina in the 3rd trimester. The fetal brain and the placenta are limited in 
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their capacity to produce LC-PUFAs (1). Thus, it is important that maternal intake 
is adequate to allow for sufficient fetal uptake.  
Dietary intake of DHA is low in many western countries, and therefore a 
dietary supplement during pregnancy may be needed (16). Smithers et al. states 
that some researchers suggest a supplement of 200 mg/day of DHA during 
pregnancy, but they conclude that recommendations for supplement amounts are 
varied (16).  Recommendations have come from expert groups, but there is 
currently not an official organization with a recommendation for an amount of 
DHA intake (e.g., the IOM DRIs address omega-3 LC-PUFA only by reference to 
intake of the precursor, α-linolenic acid).  
In 2007, European Commission research project committees, the PeriLip 
Steering Committee (PERILIP) and the Project Coordinating Committee of the 
Early Nutrition Programming Project (EARNEST), made recommendations of 
DHA intake during pregnancy and lactation based on extensive review of 
scientific evidence as well as through a general consensus workshop with 
international experts on the matter (17). Their conclusions are similar to that of 
Smithers et al., and address lactation requirements as well. These groups 
concluded that the evidence suggests that DHA is the only dietary fatty acid that 
should increase during pregnancy and lactation in most women. They concluded 
that arachidonic acid (ARA) is more important postnatally (17). After reviewing 
the many randomized control trials providing pregnant women with anywhere 
from 200-1200 mg DHA/d, the European Commission committees concluded 200 
mg DHA per day for pregnant and lactating women is appropriate (17). 
 7 
Preformed-formed dietary DHA intake is best because the plant-based omega-3 
fatty acid, α-linolenic acid, is not efficiently converted to DHA (17). Therefore, the 
committees suggest 200 mg DHA per day through fish oil supplement intake or 
one to two servings of sea fish per week (17).  
Through the consensus report, Seafood Choices: Balancing Benefits and 
Risks (18), the Institute of Medicine recommends that pregnant and lactating 
women adhere to guidelines for good nutritional intake that include two servings 
of seafood per week, for a serving size of four ounces raw or three ounces 
cooked seafood. The highest amounts of DHA are found in fatty fish including 
Atlantic salmon, Pacific and eastern oysters and rainbow trout (18). Other highly 
recommended sources include sardines and halibut (19). Government 
recommendations caution against consumption of swordfish, tilefish and shark 
and suggest limiting albacore tuna to six ounces per week during pregnancy and 
lactation due to concerns about methyl mercury (18, 19).  One paper 
recommends consumption of omega-3 fatty acids during pregnancy through 
intake of fish without high concentration of methylmercury rather than fish oil 
supplements due to the higher likelihood of the fish oils containing contaminants, 
(19) however, it has been shown that most fish oils do not contain environmental  
contaminants. While the highest dietary sources of DHA for children and adults 
include fish and fish oils, human milk is the primary source of DHA for infants (20, 
21). As of 2002, a majority of US infant formulas have been fortified with the 
addition of LC-PUFA’s DHA and arachidonic acid (ARA) (21).  
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Potential Mechanism 
 Fatty acids and iron are important for optimal brain growth and function, 
and associations between the two at a metabolic level provide plausibility for my 
proposed research questions (4, 22). The brain concentration of both iron and 
DHA suggests the potential for neuronal interactions. Both nutrients are 
important for normal myelination. While DHA is a major component of grey 
matter of the brain, a deficiency in brain DHA accumulation such as occurs in the 
peroxisomal disorder, Pseudo-Zellweger Syndrome results in inadequate brain 
myelination (23).  Iron is required for the myelination of cerebellar folds in the 
white matter of the brain, along with that of the spinal cord (24, 25). Delta-6 
desaturase, an enzyme that aids in the synthesis of DHA requires iron as a 
cofactor (1). Iron contains catalase, an enzyme that may reduce peroxidation of 
LC-PUFA such as DHA in membranes.  With respect to oxidative stress, this 
interaction between adequate iron intake and DHA is possibly beneficial (26). 
Inflammation can result from oxidative stress, leading to potential memory 
deficits (27). Finally, both DHA and iron have been shown to influence function of 
the monoamine neurotransmitter, dopamine (28-30).  
Dopamine is related to many physiological roles in the body, as it is known 
as the main neurotransmitter associated with reward functions (31). The 
existence of individual roles of iron and DHA with dopamine is well established. 
When DHA brain content was decreased through an α-linolenic acid deficient diet 
in a rodent study, dopamine receptors were altered in a way similar to that of 
many animal study findings of dopamine receptor alterations in relation to 
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depression (28). Erikson et al. showed that iron-deficiency in the rat model leads 
to decreased density among dopamine receptors (29). Another study showed 
that marginal iron intake during the developmental period of mice, when 
compared to adequate iron intake, led to not only decreased brain iron 
concentrations, but also altered biochemical status including disrupted dopamine 
metabolism (30).  
Studies on both DHA and iron suggest potential dopaminergic outcomes 
when the two nutrients interact (2, 3). One of the recent studies examining 
combined and individual provision of iron and DHA/EPA on children theorized 
that these nutrients together produce a lesser inflammatory response than when 
administered alone and that the negative cognitive outcomes seen in their study 
with individual provision of DHA/EPA to IDA children may be due to a greater 
inflammatory response, as this nutrient was supplemented without the other in 
the case of a dual deficiency (2) However, DHA and EPA are both know to have 
anti-inflammatory effects, so this seems unlikely. Also, a recent study providing 
various combinations of iron and DHA/EPA to replete male rats with both ID and 
DHA deficiency suggested that repletion with a single nutrient exacerbated 
existing deficits caused by the dual deficiency, affecting the dopaminergic 
pathway differently than when dual repletion was provided (3).  
Cognitive Assessment 
 The Bayley Scales of Infant Development (BSID) is a common 
assessment tool for cognitive function and is the primary assessment tool that 
will be used in this study. Although both are commonly seen in current research, 
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the BSID-III was published in 2005 and is the most current version of the Bayley 
Scales, updating the 1993 published BSID-II with the division of the mental 
developmental index (MDI) measurement into two different cognitive and 
language analyses as the major revision. The BSID seems to be a consistent 
measurement about studies examining DHA and cognition, with some studies 
looking at iron in relation to cognition with this testing method as well. The BSID 
has the capability of measuring language, motor and cognitive development. It 
does so by examining a wide variety of tasks including body control, coordination 
of muscles, sensorimotor development and memory and is generally used on 
infants and children <42 months of age. (32-35) 
Maternal Iron Status on Cognitive Development   
Animal studies have examined iron and neurologic relationships more 
extensively than human studies for the obvious reason that more invasive 
procedures may be employed in animal models. Iron-restriction in pregnant rats 
allowed researchers to determine that perinatal ID is associated with decreased 
size of the hippocampus and neurochemical alterations in the adult rat even if the 
concentration of brain iron is corrected after birth (36). Although brain-iron 
concentration recovered to that of the control group, hippocampal size remained 
12% smaller in the group of rats made iron deficient prior to birth (36). This 
implies that neural deficits caused by ID are not fully reversible despite 
supplementation. This outcome is related to a conclusion from a 2011 review of 
long-term consequences of ID and behavior in humans. That review concluded 
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early ID is associated with neurobehavioral impairment regardless of later normal 
iron status (4).  
Although the developmental effects of ID can be tested more readily in rat 
models, several human studies have attempted to examine both the acute and 
long-term effects of ID and supplementation (4, 37).  A recent study in western 
China concluded that iron supplementation alone was not responsible for 
increased developmental outcomes in children (35). This study used the BSID to 
assess development at three, six, and twelve months of age among offspring of 
women supplemented with either a multi-micronutrient supplement, folic acid, or 
folic acid and iron from early in the second trimester until delivery (35). Increases 
in mental development measured by the BSID were seen among all supplement 
groups, but only the multi-micronutrient supplement, which included 30 mg of iron, 
led to significant increases in mental development at twelve months. The 
increase was not found in women supplemented daily with 60 mg of iron and folic 
acid (35). The data suggest that a multi-micronutrient supplement that includes 
iron may be more beneficial for mental development than the provision of iron 
with only one other nutrient. 
Results of human studies examining long-term effects of ID vary, but most 
literature suggests that there are long-term adverse consequences of ID on 
neural development and behavior (4). Supplementing pregnant women with 20 
mg of iron per day from the middle of gestation until term led to a significant 
reduction in IDA among mothers in the iron supplemented group, but 
supplementation did not result in significantly increased intelligence quotients 
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among offspring at 4 years of age (37). In Nepal, a study supplemented mothers 
with daily iron and folic acid, iron and zinc, or multiple micronutrients beginning 
early in pregnancy.  The investigators found that iron and folic acid was the only 
combination to significantly increase intellectual and motor function when 
children reached seven to nine years of age (38). This suggests that perhaps 
there is an interactive effect of iron and other nutrients that leads to varying 
developmental outcomes.  
DHA Supplementation on Cognitive Development 
The importance of consuming adequate DHA to allow for proper uptake 
and concentration in the brain and retina is supported by a majority of studies 
reviewing DHA intake and visual acuity. It is possible that the timing of 
administration, whether DHA is supplemented during pregnancy or after birth, is 
most important for early visual outcomes (16, 21, 39, 40). Consistent with other 
studies examining DHA supplementation, through formula containing LC-PUFA’s 
DHA and ARA, postnatal administration to children results in supported visual 
development. When varying concentrations of DHA supplemented formula are 
provided to formula fed infants through one year of age, those receiving any 
formula with DHA concentration of at least 0.32% show significantly higher visual 
acuity than those receiving control formula (21). The effects of feeding formula 
with DHA on visual development remained positive through 39 months of age 
(40).  
When DHA is increased during pregnancy the effect on visual acuity is 
inconsistent. For example, Innis et al. show higher visual acuity in two-month-old 
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infants of Canadian mothers who received a daily DHA dose of 400 mg DHA 
during pregnancy (measured by the Teller Acuity Card Procedure) (39). However, 
a more recent study from Australia does not support maternal supplementation of 
an even higher dose of 800 mg DHA per day during pregnancy and increased 
infant visual acuity (by measurement of visual evoked potential) at four months of 
age, however these mothers may have been DHA deficient prior to beginning 
supplementation (16). Both of these studies began DHA supplementation after 
16 weeks gestation, facilitating DHA uptake in the third trimester when uptake 
into the brain is at the highest rate in intrauterine life (15, 16, 39). 
The BSID is a frequently used measurement of cognition among 
researchers (32, 33, 40). Supplementing enteral feeds for pre-term infants until 
adjusted full-term age did not result in significant increases in cognitive 
development at 18 months of age, but did suggest a sex-dependent relation as 
BSID MDI scores in females were increased (32). In another study, DHA 
supplemented formulas with varying amounts of DHA fed to full-term infants 
through one year of age led to significant improvements in cognition at 18 
months of age (33). Higher cognitive function was also found through 39 months 
of age when infants are fed a DHA supplemented formula through the first year 
of life (40). Few studies have gone on to relate motor development stemming 
from increased neural development, but DHA supplemented formulas throughout 
the first year of life may also be related to faster development of motor skills, 
particularly sitting without support (41). 
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 In comparison to infant supplementation with DHA, maternal 
supplementation during pregnancy has not to date shown a direct effect on 
developmental outcomes based on the BSID but may be better shown by other 
neurological measures (34, 42). Offspring of women supplemented with 800 mg 
of DHA and 100 mg of EPA per day for at least the last half of pregnancy did not 
have higher BSID scores at 18 months (34). A study examining supplementation 
to pregnant women with 500 mg DHA and 150 mg EPA per day for a similar time 
frame looked at neurological development at a later age and found that a higher 
DHA concentration in cord blood was related to developmental improvements at 
five and one-half years of age (42). This suggests that developmental 
assessments other than the BSID or assessments later than 18 months of age 
may be more sensitive to the effects of DHA supplementation during pregnancy.  
 Another issue is that DHA status is highly variable among women within 
and among populations. It is possible that failure to find an effect of 
supplementation is due to this variability and significant overlap in DHA status 
between DHA supplemented and not supplemented groups. To illustrate this, 
several randomized trials have not found an effect of supplementation; however, 
these same studies show a significant effect of maternal DHA status at delivery 
on infant development. There are also many observational studies, which show 
this same finding. 
Iron and DHA During Pregnancy and Development 
Studies examining the relationship between iron and DHA status are 
limited. Human studies on the topic are becoming an area of interest. One study 
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examined the relationship between maternal iron and DHA status with cognitive 
performance on offspring at six months of age but found no significant 
relationship (1). However, it is possible that confounding variables played a role 
as this was an observational study and did not control for factors such as 
prenatal iron supplementation, DHA supplementation or breastfeeding (1). As 
well, only 3.2% and 9.5% of mothers in this study had IDA or were anemic, 
respectively (1).  
Two recent studies have examined the effects of DHA repletion in the 
presence of inadequate iron stores (2, 3). Baumgartner et al. recently completed 
a study on male rats suggesting a negative effect of DHA/EPA supplementation 
on those with a dual deficiency of LC-PUFA’s and iron, shown by decreased 
spatial and memory performances (3). The same first author showed a similar 
effect in children ages six to eleven years (2). All children in the study population 
were ID, on the basis of one of three markers including SF <20 µg/L, sTfR >8.3 
mg/L, or zinc protoporphryin >70 µmol/mol heme (2). Nearly 20% of the children 
in this population were anemic, though in many cases not due to ID (2). After 
eight and one-half months of DHA/EPA supplementation (420 mg DHA and 80 
mg EPA provided with or without combination of 50 mg iron), the researchers 
found that working memory was significantly decreased in DHA/EPA 
supplemented subjects who were anemic at entry to the study (2). The study also 
found a sex-specific effect of DHA/EPA supplementation on long-term memory of 
subjects who were ID upon entry, with girls showing a negative response in 
testing and boys actually performing better (2).  These two latter studies imply an 
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underlying negative interaction resulting from DHA/EPA supplementation in 
animals or individuals with ID; however, relationships of cognitive function to iron 
status earlier in development would be of interest.   
Conclusion 
It is clear that both iron and DHA are important for optimal brain 
development and that the two are related at the metabolic level. A 2006 review 
evaluated the connection between iron and DHA in relation to infant’s functional 
outcomes, but concluded the evidence was inadequate due mainly to too few 
studies of the subject (43). Similar studies to those analyzed in this review of 
literature led to the suggestion that the high prevalence of ID in pregnancy and 
potential metabolic interactions between iron and DHA during the perinatal time 
frame warrant the need for large, long-term studies analyzing iron and LC-PUFA 
interactions at the metabolic level for nutrient interaction and possible detrimental 
effects on cognition (43).  Since then, two studies have shown a negative 
interaction between DHA/EPA supplementation and either a deficiency in only 
iron or in both LC-PUFA’s and iron (2, 3). The aim of my study is to examine 
DHA and iron in relation to early developmental outcomes. The study was 
undertaken with the hypothesis that DHA supplementation would enhance infant 
development, however, recent studies suggesting a potential for harm from DHA 
in ID (2,3). My study took advantage of a cohort of women randomly assigned to 
DHA supplementation and whose iron and DHA status at delivery were known 
and whose offspring had been scored on the BSID MDI and PDI. 
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Chapter 3 
METHODS 
Overview 
Analysis of DHA and iron status, and early cognitive development are 
secondary or tertiary outcomes of the KU DHA Outcomes Study (KUDOS), a 
Phase III Clinical Trial initiated in 2006 in Kansas City, KS. The KUDOS study is 
a two-phase project. The first phase examined the safety and efficacy of 
administration of 600 mg/day of DHA to pregnant women while the second phase 
consisted of a postnatal follow-up on visual and cognitive outcomes in infancy 
and childhood related to DHA administration. Subjects in the control group were 
provided 3 – 500 mg capsules of placebo oil while those in the treatment group 
were provided 3 – 500 mg total fatty acid capsules, containing a total of 600 mg 
DHA per day. Women were instructed to consume the randomized capsules from 
enrollment until delivery, which was approximately during the last two trimesters 
of pregnancy. The postnatal follow-up phase of the study did not include an 
intervention and has been completed through 18 months of age.  
The specific aims of the KUDOS study were to: 1) determine whether 
maternal RBC-phospholipid-DHA (RBC-PL-DHA) can be significantly increased 
by supplementation, 2) assess the effect of DHA supplementation on duration of 
gestation, 3) evaluate adverse events in women and infants in the treated and 
placebo groups, 4) evaluate the effect of maternal DHA supplementation on 
visual evoked potential acuity in infancy and 5) to evaluate the effect of DHA 
supplementation on the development of fundamental measures of cognitive 
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function in infancy.  I used this sample to investigate the DHA and iron status of 
the mother at delivery in relation to early cognitive and motor development of her 
offspring. 
Sample 
Subjects of the KUDOS study included 350 enrolled pregnant women 
between the ages of 16 to 35.99 years. All women were randomized to consume 
either capsules of DHA or a placebo for consumption during the time from 
enrollment into the study to delivery, were available to be contacted frequently by 
telephone and agreed to be available for postnatal study visits.  
Women were excluded from the study if serious health conditions existed 
to negatively influence pregnancy outcomes, including those that may affect the 
growth and development of the fetus and postnatal newborn as well as the health 
of the mother.  Maternal health risks that put subjects up for exclusion at baseline 
included but were not limited to cancer, lupus, hepatitis, diabetes mellitus (Type I, 
Type II, gestational) or HIV/AIDS. Women carrying multiples during pregnancy 
were excluded due to risk of increased fetal complications. Other baseline 
measurements that excluded the subject were morbid obesity (BMI ≥ 40) and 
elevated high blood pressure (systolic ≥ 140). Women were also excluded if they 
were non-English speaking due to lack of standardization of postnatal tests for 
multiple cultural groups.  
Recruitment and Research Setting 
Women between 8 and 20 weeks gestation were primarily recruited in OB 
clinics at Truman Medical Center (Kansas City, Missouri), St. Luke’s Hospital 
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(Kansas City, Kansas), and the University of Kansas Medical Center (Kansas 
City, KS) for inclusion into the study. Upon enrollment the subjects were 
presented with a background, purpose, benefits and risks of the study before 
officially enrolled. After enrollment, prenatal data was collected at the respective 
hospitals of study subjects and postnatal data was collected at follow-up visits at 
the University of Kansas Medical Center. Postnatal visits took place when the 
infant was 6 weeks, and 4, 6, 9, 10, 12, and 18 months of age.   
Ethics 
The KUDOS study was approved by the Human Subjects Committee at 
the University of Kansas Medical Center (HSC#10186). Subjects accepting 
participation in the study provided written, informed consent (see Appendix A). 
Welfare of the study subjects was upheld in accordance to the guidelines from 
the Declaration of Helsinki. Health Insurance Portability and Accountability Act 
(HIPPA) disclosure information was also provided to subjects. All research team 
personnel abided by University confidentiality policies, the Privacy Protection for 
Research Subjects, and remained current in NIH Human Subjects protection and 
HIPAA certification. Patient confidentiality was maintained throughout the study. 
Subjects received a random identification number, and this number along with 
patient initials was used for identifying infants during postnatal follow-up visits. 
Patient information was stored in a location accessible only by approved study 
protocol members.  
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Procedures 
 This sub-study design was a retrospective cohort study to examine a 
possible association between iron and DHA in relation to early cognitive 
development.  
Personnel who were trained for consistency completed blood collection 
and fatty acid analysis. Maternal blood samples were drawn at enrollment and 
the morning after childbirth. Blood was collected from an antecubital vein in 
EDTA and placed on ice. Infant blood, collected in the same manner as maternal 
samples, was obtained from cord venous blood at delivery and from an 
antecubital vein at 4 months of age. Blood was centrifuged, plasma was removed 
and the precipitated RBCs were washed three times with EDTA and stored at -80 
C until analysis. RBC lipids were extracted and left as organic solvents. 
Phospholipids (PL) were isolated by thin later chromatography. Individual fatty 
acid methyl esters were separated by gas chromatography. Peaks from this 
process were identified by comparison to authentic standards and a weighed 
standard mixture was used to adjust fatty acids for area/weight to calculate a final 
percent weight of total fatty acids. RBC-PL-DHA is reported as a percentage of 
total fatty acids by weight.  
Maternal iron status was determined by quantifying hemoglobin (Hb), SF, 
sTfR and by calculating BI from SF and sTfR. Anemia was defined as Hb less 
than 11 g/dL in the first and third trimesters while severe anemia was defined as 
Hb less than 7 g/dL during this same timeframe (8). Those pregnant women with 
SF levels less than 15 µg/L were classified as ID (8). More sensitive indicators 
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during this timeframe, including sTfR and BI were used to further investigate iron 
stores. ID, with respect to these indicators, was considered with sTfR values ≥8.4 
µg/mL (test kit value) and negative BI (mg/kg) (11, 44). The following equation 
was used to calculate BI from the sTfR/SF ratio, also known as the R/F ratio: – 
[log(R/F ratio) – 2.8229]/0.1207 (45). 
We used the same measures to quantify infant iron status with the 
exception of Hb, which was not measured in infant blood samples.  SF values 
<10 µg/L were used to classify ID in these infants (46). We used the same sTfR 
and BI concentrations to indicate ID in infants as we used for maternal 
measurements.  
The BSID-II is the primary assessment tool used in this study for cognitive 
(MDI) and motor (PDI) testing.  These BSID subtests were performed at 18 
months of age to yield IQ-like scores representing developmental sensorimotor 
milestones and basic skills representing cognitive development.  
The Peabody Picture Vocabulary Test (PPVT) was administered to 
mothers in the study, but in a few cases, it was given to fathers or grandparents 
when mothers were not available. This vocabulary assessment test was used in 
assessing the potential for confounding associations between parental 
intelligence and cognitive outcomes.  
A nutrient database created by Mallory Bratton, MS, RD, as part of her 
thesis project was the source of information on whether a separate iron 
supplement was consumed on the advice or recommendation of the woman’s 
physician.  
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Statistical Analysis 
Summary statistics of maternal and infant iron and DHA status are reported 
as mean ± SD, while minimum and maximum values are also reported. BSID 
outcome measures are also reported as mean ± SD. Decimals of all mean values 
are rounded to the nearest tenth. Iron measures are categorized in accordance 
to the values previously discussed as indicators of low iron status. As study 
personnel other than the PIs remain blinded to the DHA supplementation, we 
used a median split of maternal and infant DHA status at delivery to categorize 
women as having low or normal DHA status. Maternal and newborn iron and 
DHA values and BSID outcomes were compared by measuring correlation 
coefficients. T-tests were used to investigate the relationship between low and 
high maternal iron and DHA status and BSID outcomes. Simple descriptive 
statistics were used to report the BSID outcomes based on a potential interaction 
between iron and DHA status.  
Analysis of variance (ANOVA) was used to evaluate the interaction between 
DHA and iron status on the BSID MDI and PDI scores, however, we also did 
preplanned comparisons between ID women with a DHA status above and below 
the median in relation to infants BSID MDI and PDI scores.  We also used 
ANOVA controlling for maternal education, income by zip code, and PPVT to 
evaluate the interaction between DHA and iron status on the BSID MDI scores. 
Correlation coefficients and t-tests were used to assess other data of interest. All 
t-tests were two sample t-tests assuming equal variance. Data were analyzed by 
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IBM SPSS Software 20.0 and P values less than 0.05 were considered 
statistically significant.   
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Chapter 4 
RESULTS 
Subject Characteristics 
We studied a subset of 271 women who were among the 350 recruited 
into the KUDOS study for evaluation of DHA supplementation and pregnancy 
outcomes. The subset of women included those with a blood sample available at 
delivery. All available data from the narrowed population were used to generate 
summary statistics, simple correlations and t-tests (n =100 to 271). Of the infants 
born to these women, we had a valid 18 month BSID MDI for 194 children and a 
valid PDI for 196 children. A total of 191 pregnancies had maternal iron and DHA 
status postpartum and BSID scores on the offspring at 18 months.  Maternal and 
infant summary statistics are displayed in Table 1. 
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TABLE 1. Summary statistics of maternal and infant populations 
Characteristic Mean ± SD Min – Max 
Maternal1   
     Race (%white / %black / %other) 64/35/1  
     Age at enrollment (y) 25.7 ± 4.8 16.06 – 35.97 
     Education (y) 14.3 ± 2.8 8 – 20 
     Income by zip code ($) 46,610.5 ± 17,766.9 18,333 – 100,289 
     Number of living children 0.9 ± 1.0 0 – 5 
     BMI at enrollment (mg/kg2) 27.1 ± 26.5 16.53 – 42.56 
     PPVT  99.6 ± 14.9 67 - 100 
Infant3   
     Gender (%male / %female) 52/48  
     Race (%white / %black / %other) 65/29/6  
     Birth weight (g) 3,317.6 ± 534.3 1,010 – 4,704 
     MDI  97.0 ± 11.6 71 – 135  
     PDI  94.5 ± 9.2 71 – 119  
1Two hundred seventy-one values for age at enrollment, number of past living children and BMI at 
enrollment, 270 values for race, 266 values for income by zip code, 231 values for education, 209 values for 
PPVT. One hundred ninety PPVT exams given to mother, 18 given to father, 1 given to grandmother. 
2Two hundred seventy-one values were available for birth weight, 270 values for gender, 223 values for 
race, 196 values for PDI, 194 values for MDI. 
 
Nutritional Status 
 With the exception of Hb, all maternal iron status markers were drawn at 
delivery and are referred to as postpartum iron markers. The mean and median 
values and ranges for maternal and infant measures of iron and DHA status are 
shown in Table 2.  We also included the descriptive analyses of iron and DHA 
status of the infants for whom blood was obtained at 4 months of age, however 
these were not evaluated further because there were many missing data. 
 According to conventional concentrations for iron status biomarkers, 12% 
(n=29) had ID by sTfR concentration, 29% (n=71) by SF and 18% (n=43) by BI. 
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Anemia occurred in 5% of the women during the first trimester of pregnancy and 
in 25% during the third trimester of pregnancy (n=63).  
 Fifty-one percent (n=86) of the infants had a cord sTfR ≥8.4 mg/L, 
however, we do not conclude that this many were ID, because there are no 
standards for sTfR in cord blood. Using SF and BI, which may be more reliable 
indicators in newborns, one infant had ID according to cord SF while also only 
one infant had ID according to cord BI, however these were two different subjects. 
At four months of age, 11% of the infant population had ID according to sTfR. 
Two infants had ID according to both 4-month SF and 4-month BI. These were 
the only two infants with ID according to these individual markers.  
 All maternal DHA values reported and discussed in this study were drawn 
at delivery. A median split was used to classify those with lower DHA status from 
those with higher DHA status. Infant DHA values were assessed in cord blood as 
well as at 4-months of age. As with the maternal population, a median split was 
used to classify the infant population with lower DHA status from that with a 
higher DHA status. Summary statistics of maternal and infant iron and DHA 
status are shown in Table 2, followed by a description of the maternal and infant 
populations with low iron or DHA status in Table 3. 
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TABLE 2. Summary statistics of maternal and infant iron and DHA status 
Characteristic Mean ± SD Median Min – Max 
Maternal iron1     
     Postpartum sTfR (mg/L) 5.4 ± 2.9 4.67 0.19 – 19.52 
     Postpartum SF (µg/L) 27.1 ± 27.1 27.13 3.35 – 208.40 
     Postpartum BI (mg/kg) 4.3 ± 4.0 4.98 -6.85 – 14.95 
     First trimester Hb (g/dL) 12.6 ± 0.9 12.6 9.9 – 15.4 
     Third trimester Hb (g/dL) 11.5 ± 1.0 11.5 8.4 – 14.0 
Infant iron2    
     Cord sTfR (mg/L) 8.9 ± 2.8 8.43 0.85 – 19.73 
     Cord SF (µg/L) 149.0 ± 93.9 127.87 9.53 – 650.31 
     Cord BI (mg/kg) 8.3 ± 2.7 8.37 -0.03 – 14.86 
     4-month sTfR (mg/L) 6.5 ± 1.5 6.25 3.19 – 12.83 
     4-month SF (µg/L) 67.4 ± 44.2 59.00 6.78 – 257.51 
     4-month BI (mg/kg) 6.3 ± 2.7 6.54 -3.76 – 12.41 
Maternal DHA3    
     RBC-PL-DHA 6.1 ± 2.0 5.47 2.30 – 12.26 
     Plasma-PL-DHA  4.3 ± 1.6 3.91 1.54 – 9.12 
Infant DHA4    
     Cord RBC-PL-DHA  6.6 ± 1.8 6.49 2.32 – 11.68 
     Cord plasma-PL-DHA  4.9 ± 1.8 4.54 2.10 – 12.14 
     4-month RBC-PL-DHA  6.2 ± 1.8 5.87 2.78 – 14.08 
     4-month plasma-PL-DHA 4.5 ± 1.3 4.29 1.94 – 9.98 
1Two hundred sixty-five values were available for first trimester Hb, 254 values for third trimester Hb, 243 
values for postpartum sTfR, 242 values for postpartum SF and postpartum BI. 
2One hundred sixty-nine values were available for cord sTfR, 166 values for cord SF, 165 values for cord BI, 
115 values for 4-month sTfR, and 100 values for 4-month SF and 4-month BI. 
3Measured in g/100g Total FA. Two hundred sixty-three values were available for RBC-PL-DHA and 
plasma-PL-DHA. 
4Measured in g/100g Total FA. One hundred ninety values were available for cord RBC-PL-DHA, 189 values 
for cord plasma-PL-DHA, 143 values for 4-month plasma-PL-DHA, 126 values for 4-month RBC-PL-DHA. 
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TABLE 3. Maternal and infant populations classified with low iron or DHA status 
Characteristic  Standard1 % Population2 
Maternal iron marker3    
     Postpartum sTfR   ≥ 8.4 mg/L 12 
     Postpartum SF   <15 µg/L 29 
     Postpartum BI   <0 mg/kg 18 
     First trimester Hb   <11 g/dL 5 
     Third trimester Hb   <11 g/dL 25 
Infant iron marker4    
     Cord sTfR   ≥ 8.4 mg/L 51 
     Cord SF  <10 µg/L 0 
     Cord BI  <0 mg/kg 0 
     4-month sTfR  ≥ 8.4 mg/L 11 
     4-month SF   <10 µg/L 2 
     4-month BI   <0 mg/kg 2 
Maternal DHA marker5    
     RBC-PL-DHA  5.47 50 
     Plasma-PL-DHA   3.91 50 
Infant DHA marker6    
     Cord RBC-PL-DHA   6.49 50 
     Cord plasma-PL-DHA   4.54 50 
     4-month RBC-PL-DHA   5.87 56 
     4-month plasma-PL-DHA  4.29 51 
1Conventional standards used to describe iron status. Maternal sTfR, SF and BI indicate ID. Maternal Hb 
indicates anemia. Infant iron standards indicate ID. DHA status represented in g/100g Total FA and based 
on median split. 
2Percent of population with values < standard used for iron status and ≤ standard used for DHA status. 
3Two hundred sixty-five values were available for Hb first trimester, 254 values for Hb third trimester, 243 
values for postpartum sTfR, 242 values for postpartum SF and postpartum BI. 
4One hundred sixty-nine values were available for cord sTfR, 166 values for cord SF, 165 values for cord BI, 
115 values for 4-month sTfR, and 100 values for 4 month SF and 4-month BI. 
5Two hundred sixty-three values were available for RBC-PL-DHA and plasma-PL-DHA. 
6One hundred ninety values were available for cord RBC-PL-DHA, 189 values for cord plasma-PL-DHA, 143 
values for 4-month plasma-PL-DHA, 126 values for 4-month RBC-PL-DHA. 
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Individual Maternal Iron and DHA Markers in Relation to BSID Scores 
 Correlations between the BSID outcomes and maternal iron and DHA 
status were run to view potential relationships. The relationships between all 
maternal iron status markers assessed, as well as those of all maternal DHA 
markers assessed, and respective infant cognitive outcomes are shown in Table 
4. The only significant correlations seen between maternal iron markers and MDI 
scores were hemoglobin measurements in the first and third trimester, which 
were both positive correlations. Postpartum SF and RBC-PL-DHA were 
significantly negatively correlated with PDI scores.  
 
TABLE 4. Correlations between maternal iron and DHA markers and BSID 
outcomes 
 MDI PDI 
 r r 
Postpartum sTfR  -0.107 0.031 
Postpartum SF  0.043 -0.162* 
Postpartum BI  0.079 -0.101 
First trimester Hb 0.167* -0.048 
Third trimester Hb  0.165* -0.029 
RBC-PL-DHA  0.081 -0.157* 
Plasma-PL-DHA 0.109 -0.086 
*Correlation is significant at p<0.05 
   
 
In further analyses, BSID outcomes of respective high and low maternal 
iron and DHA status were examined. When comparing the MDI or PDI scores of 
mothers with high iron status and mothers with low iron status, no significant 
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difference was found based on postpartum sTfR. When comparing the MDI or 
PDI scores of mothers with high iron status and mothers with low iron status, no 
significant difference was found based on postpartum BI. When comparing the 
MDI or PDI scores of mothers with high RBC-PL-DHA concentrations and 
mothers with low RBC-PL-DHA concentrations, no significant difference was 
found. These data are shown in Table 5. Conventional markers used to classify 
high and low maternal iron and DHA status for this analysis were those reported 
in Table 3.  
 
TABLE 5. Individual relationships between low and normal maternal iron and 
DHA status and BSID outcomes1 
  MDI   PDI  
 Mean 1 
± SD 
Mean 2 
± SD 
P Mean 1 
± SD 
Mean 2 
± SD 
P 
Postpartum sTfR2 94.4  
± 9.2 
97.3  
± 11.4 
0.285 97.7  
± 9.8 
94.2  
± 9.2 
0.116 
Postpartum BI3 95.3  
± 10.7 
97.3  
± 11.4 
0.374 97.2  
± 8.3 
94.0  
± 9.4 
0.093 
RBC-PL-DHA4 96.7  
± 11.7 
97.3  
± 11.5 
0.753 95.4  
± 9.5 
93.9  
± 9.0 
0.256 
1Mean 1 representing mean for ID and low DHA groups, Mean 2 representing mean for normal iron and 
DHA groups. 
2MDI: Mean 1 n=19, Mean 2 n=170. PDI: Mean 1 n=19, Mean 2 n=172. 
3MDI: Mean 1 n=29, Mean 2 n=160. PDI: Mean 1 n=29, Mean 2 n=162. 
4MDI: Mean 1 n=85, Mean 2 n=106. PDI: Mean 1 n=86, Mean 2 n=107. 
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Potential Influence Between Maternal Iron and DHA Status and Infant 
Outcomes 
To evaluate the association with maternal iron and DHA status on early 
developmental outcomes of the child population at 18 months of age, we used 
the 191 mother infant dyads with a maternal postpartum DHA blood sample and 
usable BSID scores in the final descriptive statistics and ANOVA model.  
Mother infant dyads were grouped according to maternal postpartum iron 
and DHA status. Four groupings were created for nutrient status: ID with RBC-
PL-DHA less than or equal to the median; ID with RBC-PL-DHA above the 
median; normal iron with RBC-PL-DHA less than or equal to the median; normal 
iron with RBC-PL-DHA above the median. ID was defined as either a sTFR ≥8.4 
mg/L or a BI<0 BSID MDI  (n=188) and PDI (n=190) outcomes were compared 
by iron and DHA status.  
Among all mother infant dyads with a low postpartum iron status, no 
significant difference in BSID outcomes was observed depending on DHA status. 
Results for BSID outcomes categorized by postpartum iron and DHA groupings 
are shown in Table 6. 
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TABLE 6. BSID outcomes categorized by postpartum iron and DHA1 groupings 
  MDI2  PDI3 
  Mean ± SD n  Mean ± SD n 
sTfR4, DHA groupings       
Iron Deficient, low DHA  90.1 ± 7.3 9  101.7 ± 8.9 9 
Iron Deficient, normal DHA  98.2 ± 9.4 10  94.1 ± 9.6 10 
Normal iron, low DHA  97.4 ± 11.1 74  94.6 ± 9.4 75 
Normal iron, normal DHA  97.2 ± 11.8 95  93.9 ± 9.1 96 
       
BI5, DHA groupings       
Iron Deficient, low DHA  93.3 ± 10.1 16  99.2 ± 9.7 16 
Iron Deficient, normal DHA  97.8 ± 11.1 13  94.7 ± 5.8 13 
Normal iron, low DHA  97.4 ± 11.1 67  94.4 ± 9.3 68 
Normal iron, normal DHA  97.2 ± 11.7 92  93.8 ± 9.5 93 
1DHA categorized into low DHA and normal DHA groups based on original study population median value of 
5.47 g/100g Total FA; low as RBC-PL DHA ≤ median, normal as RBC-PL-DHA > median 
2One hundred eighty-eight values available for MDI 
3One hundred ninety values available for PDI 
4sTfR categorized into ID and normal iron groups with ID as postpartum sTfR ≥ 8.4 mg/L and normal iron as 
postpartum sTfR <8.4 mg/L 
5BI categorized into ID and normal iron groups with ID as postpartum BI <0 mg/kg and normal as postpartum 
BI >0 mg/kg 
 
 
To compare the BSID MDI and PDI in relation to the maternal iron and 
RBC-PL-DHA status, MDI and PDI were entered into two separate two-way 
ANOVAs by iron status (ID or normal) and DHA status (below or above the 
median) as between subject factors. No significant outcomes were seen among 
any of the four ANOVAs ran. The MDI analysis did not yield any significant 
factors when ID was defined by sTfR: Iron Group, F (1,184) = 1.317, p = .253; 
DHA Group, F (1,184) = 2.055, p = .153; Iron x DHA, F (1,184) = 2.338, p = .128. 
The PDI analysis did not yield any significant factors when ID was defined by 
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sTfR. Iron Group, F (1, 186) = 2.668, p = .104; DHA Group, F (1, 186) = 3.428, p 
= .066; Iron x DHA, F (1, 186) = 2.377, p = .125. The MDI analysis did not yield 
any significant factors when ID was defined by BI: Iron Group, F (1, 184) = .613, 
p = .435; DHA Group, F (1, 184) = .863, p = .354; Iron x DHA, F (1, 184) = 1.075, 
p = .301. The PDI analysis did not yield any significant factors when ID was 
defined by BI: Iron Group, F (1, 186) = 2.257, p = .135; DHA Group, F (1, 186) = 
1.872, p = .173; Iron x DHA, F (1, 186) = 1.060, p = .304.  
 While MDI and PDI were significantly correlated, no other significant 
correlations were observed in conjunction for PDI. On the other hand, several 
variables correlated significantly with MDI including maternal education (r = 0.268, 
p < 0.01), income categorized by zip code (r = 0.262, p < 0.01) and maternal 
PPVT scores (r = 0.326, p < 0.01). A significant negative correlation was also 
observed between MDI and number of living children (r = -0.253, p < 0.01).  
As a result of the significant correlations observed with MDI, two-way 
ANOVAs by iron status (ID or normal) and DHA status (below or above the 
median) as between subject factors where we controlled for maternal education, 
income categorized by zip code, and maternal PPVT scores were performed. 
The results from the ANOVAs controlling for covariates were also nonsignificant. 
The MDI analysis controlling for the three mentioned covariates did not yield any 
significant factors when ID was defined by sTfR: Iron Group, F (1, 175) = .989, p 
= .321; DHA Group, F (1, 175) = .269, p = .605; Iron X DHA, F (1, 175) = 1.610, p 
= .206. The MDI analysis controlling for the three mentioned covariates did not 
yield any significant factors when ID was defined by BI: Iron Group, F (1, 175) = 
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0.22, p = .882; DHA Group, F (1, 175) = 0.85, p = .770; Iron x DHA, F (1, 175) = 
1.726, p = .191. As nothing other than MDI showed a strong correlation in 
relation to PDI, the idea that there is no need for an ANOVA controlling for 
covariates with PDI outcomes is supported.  
Because one of our questions was if DHA could actually be harmful to 
cognitive development in conjunction with ID, we compared MDI and PDI 
performance at 18 months for children of women with ID and lower DHA 
compared to ID and higher DHA. There was a nonsignificant trend toward higher 
child MDI when DHA status was higher in ID mothers, as measured by sTfR 
(p=0.054). Figure 1 shows the effects observed between iron and DHA status on 
the MDI. Figure 2 shows the effects observed between iron and DHA status on 
the PDI. 
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FIGURE 1. Iron by DHA effect on MDI (means of groupings represented) 
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FIGURE 2. Iron by DHA effect on PDI (means of groupings represented) 
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Association Between DHA and Iron Status  
 Maternal RBC-PL-DHA was significantly correlated with postpartum BI (r = 
0.265, p < 0.01) and SF (r = 0.261, p < 0.01) and also with sTfR (r = -0.191, p < 
0.01). When maternal BI of women with RBC-PL-DHA status below the median 
was compared to that of women above the median there was a difference in 
body iron (p < 0.01). The mean BI (mg/kg) for those with DHA below the median 
was 3.3 ± 4.0 while that of women with a DHA status above the median was 5.3 
± 4.0. 
Physician Recommended Iron Supplementation 
Fifty of the 191 women whose offspring had available BSID scores were 
prescribed iron by their physician. At delivery 14 of these had a ID based on a 
negative BI and/or elevated sTfR. Of these 14 women, eight reported intake of 
the iron supplement recommended by their physician. The remaining 36 women 
prescribed iron by their physician had normal iron status at delivery by BI and 
sTfR. All reported taking their recommended supplement. Of the 191 mother 
infant pairs studied, 33 women had ID by postpartum BI and/or postpartum sTfRr. 
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Chapter 5 
DISCUSSION 
Iron Status 
Through measurement of BI as the representative marker of iron status, 
the presence of ID of pregnant women examined in this study appears to 
representative of the pregnant women of the US population. A 2011 report by 
Mei et al. using BI as the representative marker examined the 1999-2006 
National Health and Nutrition Examination Survey and claims to be the first study 
to assess iron status in a representative population of US pregnant women (47). 
The latest measurement of iron status of pregnant women in the NHANES study 
was taken in the third trimester (47).  Using these markers in comparison to our 
markers at delivery, mean BI was observed to be the same in our group 
compared to that of the NHANES study  (4.3 mg/kg) (47). Mean SF of the two 
respective groups was similar (27.1 µg/L vs. 26.3 ug/L) but sTfR was higher in 
our cohort  (5.4 mg/L vs. 3.45 mg/L) than in NHANES (47). As well, the mean Hb 
in our population during the third trimester was lower (11.5 g/dL) than that of the 
NHANES study (12.6 g/dL) (47). 
Pregnant women from the NHANES study had an 18% incidence of ID by 
BI <0 mg/kg (47). Low BI was more prevalent in Mexican American and non-
Hispanic black pregnant women during the second and third trimesters of their 
pregnancy, as well as in those with a parity ≥ 2 (47). Among the pregnant women 
in our study population, the presence of ID by BI was 18%. A BI less than 0 was 
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significantly more likely to occur in mothers with parity ≥ 2 (P < 0.01). We did not 
find a relationship between maternal race and BI in our sample.  
Compared to pregnant women who have been studied in other parts of the 
world, US pregnant women appear to have less ID (10). A study in Belgium 
found the prevalence of ID to be 40% based on SF. However, it was interesting 
that this same group of pregnant women had a lower prevalence of ID based on 
sTfR (7% compared to 12% in our population) and a lower prevalence of anemia 
based on Hb (21% compared to 25% in our population (10). Only the median BI 
was reported in the Belgian women (3.6 mg/kg), but it was lower than the median 
BI of those in our population (4.3 mg/kg). Iron assessment occurred during the 
3rd trimester of pregnancy in the Belgian population while our assessments were 
made within hours after delivery (10). Nearly two-thirds of the women in the 
Belgian population claimed to have taken supplements containing iron during 
pregnancy (actual amounts of iron intake not specified), however it should be 
noted that 40% of these women were still considered ID during the third trimester 
based on SF < 15 ug/L (10). Rioux et al. studied maternal DHA and iron status 
and found the prevalence of ID in the Canadian women they studied to be 34.9%, 
based on a SF < 10 ug/L. This is much higher than in our population, which had a 
prevalence of 17% using this cut-off. (1).  
Infant iron status at delivery and during infancy does not seem to be as 
readily measured as maternal status. However, Rioux et al. found that 6.3% of 
infants were anemic at 6 months of age based on Hb stores (1). Our study did 
not measure Hb in the infant population, but it was observed that at 4 months of 
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age the prevalence of ID was 2% based on BI and 11% based on sTfR 
concentrations.  
Relevant Markers of Iron Status 
 The WHO has questioned the use of SF concentration to determine iron 
status in pregnancy because pregnancy and parturition are considered to be 
inflammatory states. Accordingly, WHO advises against its use as an iron status 
indicator during pregnancy (8). Interestingly, inflammation increases SF, yet SF 
concentration in our population suggested a much higher incidence of ID (29%) 
than did sTfR or BI, 12% and 18%, respectively.  
Even when SF is measured during pregnancy, the SF cutoff used to 
differentiate ID varies.  While SF <15 µg/L is the suggested cutoff for ID for 
females of reproductive age (8-10) and this value has been used during 
pregnancy, other references have used SF <12 µg/L and SF <10 µg/L during 
pregnancy (1, 9, 10, 48). If we used an SF concentration <12 µg/L, as our cut-off, 
ID in our population decreased from 29% (n=71) to 21% (n=52). As noted above, 
only 17% of women in our study had ID using SF<10 as the cut-off, the value 
used by Rioux et al (1).  
 As well, studies use different cut-offs for SF signifying ID in the infant 
population. The WHO uses a cut-off of <12 ug/L in children under 5 while some 
researchers suggest <10 µg/L (8, 9). We used SF <10 µg/L, a more conservative 
number, but the number of ID individuals would not have been increased at 
delivery or 4 months of age had we used a cut-off of <12 µg/L. 
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 The most selective marker of ID for pregnant women used in this study 
appears to be sTfR, however, 51% of the cord blood samples had an sTfR 
concentration ≥8.4 mg/L. We do not think elevated sTfR in cord blood is a 
reliable indicator of ID. The mean sTfR of our infant cord blood samples (8.9 
mg/L) was similar to that reported by Sweet et al. (8.4 mg/L). These authors 
speculated that the elevated sTfR in cord blood plasma most likely reflected high 
fetal requirements for erythropoiesis (49). Based on SF and BI concentrations, 
only two children in our study had ID at birth; these children did not have ID 
based on both markers as one had ID based on SF and the other had ID based 
on BI.  
 In terms of a maternal marker for ID during pregnancy, sTfR is used 
throughout the literature, however a standard value has not yet been identified. 
An sTfR >4.4 is the smallest concentration that has been mentioned in 
publications to indicate ID, however, the authors chose the value because they 
lacked a standard and because the manufacture specified range for sTfR ended 
at this value (47). Vandevijvere et al. used sTfR >8.5 mg/L to specify ID in their 
population of Belgian women, and chose this value based on this cut-off in a 
previous study in Swedish pregnant women (48). We used ≥8.4 mg/L in our 
study, because that is the cutoff used for our ELISA, however, the percentage of 
women in our study classified with ID would remain 12% had we used a cut-off of 
>8.5 mg/L. One fewer women would have been considered ID. Interestingly, she 
was considered ID by status was categorized in terms of BI. The subject also had 
a lower RBC-PL-DHA value, so she would have been lost from the ID, low DHA 
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group, leaving only 8 women with ID and lower DHA. The lower and higher DHA 
groups are already small and the effect of DHA on the MDI in ID women is not 
significant. However, it would be much easier to determine if the apparent 
protective effect of DHA on child MDI is real in a cohort that includes more 
women with postpartum ID. 
 BI was proposed as an indicator of iron status in 2003 and is not yet a 
validated marker of iron status during pregnancy (45). While it did not appear to 
be as selective of a marker of ID in our population as did sTfR, it was much more 
selective than SF, which is still seen commonly used despite suggestions against 
its use during pregnancy. BI is becoming a more common assessment tool 
during pregnancy (10, 47). 
 Hb appears to be a consistent measurement taken to view iron status 
during pregnancy, however it is not often the primary marker of focus in the 
literature. This appears to be so as Hb may be lower throughout the progression 
of pregnancy due to the increased expansion of plasma volume (8). It is often 
primarily used as a marker of iron-deficiency anemia, especially within the first 
two trimesters of pregnancy, but due to increased plasma volume its use as a 
determinant for iron status as pregnancy progresses is questioned and is 
therefore not a principal assessment marker (10, 48).  
DHA Status 
We differentiated DHA status of mother and infant based on a median split 
and used the respective values to separate those with lower DHA status from 
those with higher DHA status. Although not analyzed in relation to iron or 
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cognitive outcomes, mean and median values of plasma-PL-DHA were reported 
in addition to RBC values used in further analysis throughout our study.  
The RBC and plasma DHA levels of our maternal sample at delivery were 
higher than those reported by Rioux et al (1). Mean RBC-PL-DHA values were 
higher among our population of pregnant women at 6.1 ± 2.0 g/100g total FA in 
comparison to 4.3 ± 1.98 g/100g total FA (1). Mean plasma-DHA values were 
also higher among our population at 4.3 ± 1.6 g/100g total FA in comparison to 
2.1 ± 0.5 g/100g total FA (1). The main differences between the methodologies of 
the two studies are that Rioux et al. studied a population of pregnant Canadian 
women, took blood measurements between 28 and 32 weeks, and did not 
provide a DHA supplement (1), whereas approximately half of the women in our 
study were provided 600 mg/day of DHA for over half of pregnancy. The 
nutritional intake of Canadian women, blood draws prior to delivery, and lack of 
supplementing with DHA are all possible factors to attribute the higher DHA 
status of our population. 
In a study supplementing pregnant women with 400 mg DHA or placebo, 
Novak et al. measured maternal PL-DHA at 36 weeks gestation and infant PL-
DHA through cord blood at delivery (50). Novak et al. reported DHA values 
through analysis of the choline PL (PC) and ethanolamine PL (PE) (50). In 
comparison, the RBC-PL-DHA values of our population included all PL in the 
RBC membrane.  Given that there are approximately equal amounts of PC and 
PE in RBC PL, and these two PL classes account for approximately two-thirds of 
RBC PL, I averaged the results from PC and PE in the population studied by 
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Novak et al.  Maternal RBC-PL-DHA values of our population were 6.1 g/100g 
total FA compared to 5.34 g/100 g total FA in their study (50). Cord RBC-PL-DHA 
values of our population were also higher at 6.6 g/100g total FA compared to an 
average of PC and PE of 5.79 g/100g total FA (50).  
Whereas our study analyzed plasma-PL-DHA and RBC-PL-DHA in all 
subjects, plasma-PL-DHA content was analyzed among only 17 of the mother 
infant dyads of the initial 97 in Novak’s study (50). Plasma values of our maternal 
and infant populations were lower than those reported among the maternal and 
infant populations of Novak et al. Mean plasma-PL-DHA of our maternal 
population at delivery (4.3 g/100g total FA) was lower than that reported by 
Novak et al. (6.45 g/100g total FA) (50). The case was the same for infant cord 
measurements at a mean of 4.9 g/100g total FA in our study and 7.77 g/100g 
total FA reported by Novak et al. (50).  It is well known that RBC-PL-DHA is 
higher than plasma-PL-DHA in groups that have been studied previously, so it is 
not clear why the values found by Novak et al. were so high for plasma. There 
may have been a problem with their analysis since they also were unable to 
analyze DHA in most of their plasma samples (80 of 97). 
Association Between Iron and Cognitive Outcomes 
 When we considered all women regardless of iron status, we did not find a 
significant relationship between the BSID scores of children and the iron status of 
their mothers when assessed by sTfR or BI, which we consider the most relevant 
markers of iron status in this study and as a result of the reviewed literature. We 
did however find a significant relationship between iron status and MDI scores 
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with Hb concentrations in the first and third trimester (p<0.05). This was not 
weighed heavily due to the criticism of the fluctuation of hemoglobin and poor 
reflection of iron status during pregnancy, due to in part to increased plasma 
volume (8, 10, 48). As well, hemoglobin during pregnancy is not a primary 
marker of assessment in the literature (10, 48). Postpartum SF was the only iron 
status marker significantly correlated with PDI scores (p<0.05).  This outcome 
was not weighed heavily either, as SF has been criticized as a poorly sensitive 
marker of ID during pregnancy, although still seen in the literature (8). Few 
studies have examined maternal iron status or iron supplementation alone in 
relation to cognitive outcomes of offspring. 
Our results are somewhat similar to a study assessing maternal iron 
supplementation and child outcomes (37). In the study by Zhou et al., a 
randomized trial of prenatal iron supplementation did not show a significant effect 
of supplementation compared to placebo on IQ scores of children at 4 years of 
age (37). However, it should be noted that this study used SF < 12 µg/L as the 
primary ID indicator, while also assessing IDA by way of hemoglobin and SF 
which could not be done in our study (37). While we did see a significant 
negative correlation between maternal SF and offspring PDI, when a t-test was 
run differentiating the PDI scores based on ID according to SF, a significant 
difference in PDI scores was not seen with our cutoff of SF <15 µg/L. When 
adjusted to SF <12 µg/L for comparison to the results of Zhou et al., a significant 
difference was still not observed in the mean PDI scores of our population. 
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Although the children were assessed at an older age, BSID scores at 18 months 
do correlate modestly with IQ scores later in childhood (37).  
Association Between DHA and Cognitive Outcomes 
 We found that the BSID MDI in children did not differ by the DHA status of 
their mothers but that BSID PDI in children was significantly negatively correlated 
(p < 0.05) with maternal RBC-PL-DHA, while this difference was not observed 
with maternal plasma-PL-DHA. Current research has failed to find significant 
relationships between maternal DHA supplementation and infant cognition. To 
the best of our knowledge, our study is the first to identify a significant negative 
relationship between lower maternal DHA status and a lower outcome on the 
BSID PDI in children. This is suggestive of a negative effect of maternal DHA 
status on PDI outcomes of offspring. However, when a t-test was run on the PDI 
scores based on a median split differentiating RBC-PL-DHA, a significant 
difference was not observed. With the exception of our observation in relation to 
PDI scores and low RBC-PL-DHA, our results are consisted with the current 
research in finding no other relationships with DHA status and cognitive 
outcomes, especially on the MDI.  
Although we assessed DHA status based on a median split rather than 
viewing the supplemented and placebo groups separately in our population, half 
of the women were supplemented with DHA and we expect that supplemented 
women constitute the majority of the higher DHA group.  The study is still 
masked to all but the study Principal Investigators so we need not attempt to 
identify who received a supplement and who did not.  Makrides et al. randomized 
 47 
a large number of Austrailian pregnant women (n=2,399) to received either 800 
mg DHA per day or placebo from <21 weeks gestation until delivery and the 
BSID-III was assessed in the offspring at 18 months (n=726) (34). Because the 
BSID-III contains more testing divisions than the BSID-II, direct comparison of 
our BSID results to those of Makrides et al. is not possible (34). However, no 
significant differences in BSID outcomes were observed between the 
supplemented and supplemented groups, leading to the conclusion that maternal 
DHA supplementation does not improve infant performance on the BSID at 18 
months of age (34). That said, the BSID may not be the ideal indicator to 
evaluate early cognitive function.  More sensitive measures, and measures 
targeted to the effects of DHA on brain function have been proposed. In addition, 
it has been proposed that the effects of DHA on cognitive function may not fully 
emerge until later in childhood (1). 
Potential Interaction Between Iron and DHA and Relationship to Cognitive 
Outcomes 
 In 2006, a review by Rioux et al. suggested that large, long-term studies 
on pregnant women were in need to better understand individual and dual roles 
of iron and DHA on respective infant cognitive outcomes (43). Since then, the 
same primary author has attempted to study the relationship between the two 
nutrients with infant cognition (1). Our study appears to be the only one to 
examine both maternal iron and DHA status in relation to infant cognition other 
than Rioux et al. These investigators did not combine DHA and iron status in 
analysis with BSID outcomes. While Rioux et al. did not supplement pregnant 
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women, outcomes on the BSID-II at 6 months of age were not associated with 
maternal iron or DHA status between 28 and 32 weeks gestation (1). As noted, 
the iron status of our maternal population is difficult to compare to that of Rioux et 
al. because we have a larger percentage of women with ID based on Hb and a 
smaller percentage of women with ID based on SF. Rioux et al. did not measure 
sTfR or BI, which may be better indicators for iron status during pregnancy. Also 
previously noted, the maternal DHA status was lower than that in our population, 
and in fact all could be considered to have low DHA status because they were 
not supplemented with DHA. 
 In examining children of women who were ID at delivery (sTfR ≥8.4 mg/L), 
we saw a nonsignificant trend toward higher BSID MDI in women with a DHA 
status above the mean. Because there were so few ID women in each DHA 
group (9 and 10 in the lower and higher DHA groups, respectively), the results 
suggest a type II error. Offspring of the group of women with ID and low DHA 
status had an 8-point lower mean MDI scores compared to women with ID but 
higher DHA status. This was observed even in comparison to those women with 
normal iron status, regardless of DHA status. This may suggest a protective 
effect of DHA on cognitive outcomes when maternal iron status is low. It is likely 
that a significant protective effect of DHA was missed due to the low sample size 
of mothers with ID. 
At least one study has attempted to establish a relationship between 
supplementation with iron and DHA to establish a relationship between the 
nutritional status of children regarding the two nutrients and their cognitive 
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outcomes at an older age. Although these children were from a different country 
and were between the ages of 6-11 years, ultimately a different outcome in the 
potential relationship between the two nutrients and cognition was found between 
our studies (2). Baumgartner et al. observed potential associations between child 
supplementation with iron or DHA/EPA, or the combined nutrients, in a 
population of ID and n-3 FA-deficient children, and found that DHA/EPA 
supplementation in these children had a negative outcome on cognition in 
children with anemia and girls with ID (2).  This study prompted us to evaluate 
the effect of higher DHA status in conjunction with ID in pregnancy in relation to 
child cognitive function. As noted above, rather than seeing any suggestion of 
harm, our data support a benefit of DHA supplementation to women who are ID 
during pregnancy. 
Correlations with BSID Outcomes 
 MDI was significantly correlated with maternal education, income and the 
PPVT score, a means of evaluating parent IQ. A negative relationship was 
observed between parity and the MDI. It was thought that these factors could be 
related to the outcomes seen on the MDI in comparison to maternal iron and 
DHA status. Outcomes of ANOVAs run with maternal education, income and 
PPVT as covariates to the MDI showed the relationships to still be nonsignificant.  
Association Between DHA and Iron Status 
 Our results showed that maternal DHA status might have an effect on 
maternal iron status. Higher RBC-PL-DHA status was significantly related to 
higher BI concentration in the mothers of our study population, although this 
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difference was not observed when DHA was analyzed in accordance to sTfR 
status, perhaps because more women had ID by BI than by sTfR. Because 
women with a higher DHA should represent predominantly women who received 
DHA supplements, this finding suggests that DHA might actually improve iron 
status. So far we do not have a plausible mechanism to suggest, however a 
similar result was observed in baboons supplemented with different amounts of 
DHA and ARA compared to placebo with neither DHA nor ARA. While a potential 
interaction between the two indicators is suggested here, we note that BI is not 
yet a validated marker of iron status during pregnancy. To our knowledge, the 
relationship between BI and DHA has not been observed in other studies 
examining the two nutrients in accordance with one another.  
Physician Recommended Iron Supplementation 
 Not all mothers with a postpartum ID based on sTfR or BI were advised to 
take iron during pregnancy. Of the women who were prescribed additional iron 
that were included among the 191 mother infant dyads studied here, 50 women 
were advised to take an iron supplement. At delivery, 14 of the 50 had ID.  The 
remaining 36 women did not, but this may be because they were given an iron 
supplement.  
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Limitations 
Although this data collection from previous research has been improved 
over time, limitations still exist in this project. Due to delivery at outlying hospitals, 
cord bloods were not obtained for all pregnancies for which we have maternal 
blood at delivery.  Also, mother infant dyads who had blood drawn but did not 
complete the BSID appointment are excluded, therefore limiting the sample size 
of this study.  Another limitation to this study is a lack of previous work in 
pregnant women to clarify the best biomarkers for ID and a lack of consistency in 
the literature, which limits our ability to compare the results of our study with 
those of others.   
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Chapter 6 
SUMMARY 
Our sample population appears to have similar iron status to that of US 
women. However, inconsistency among use of appropriate iron markers made it 
difficult to compare the iron status of our population to that of other countries. 
The DHA status of our maternal population was also relatively similar to that 
reported in the literature for US women when we looked at ID and DHA status 
prior to supplementation.  
Outcomes between individual maternal iron and DHA status on infant 
cognition do not seem to differ significantly from the limited findings available for 
review, however, we found a potential association between maternal ID and DHA 
status in relation to infant cognition. We found a potentially positive and 
protective effect of DHA when maternal iron status is low. We observed a 
significantly negative correlation with maternal RBC-PL-DHA status and offspring 
PDI outcomes, however when analyzed based on the median split of our 
population, a difference in the means was not significant.  
Future research is needed to assess proper iron status markers during 
pregnancy on mother and child, while validation of BI as an assessment tool 
during this timeframe should be considered. Further studies including a larger 
number of women with ID, while also paying close attention to DHA status, are 
needed to assess the relationship between iron and DHA status on respective 
infant cognitive outcomes.   
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CONSENT FORM 
The Effects of DHA on Pregnancy and Infant Outcome 
(Kansas University DHA Outcomes Study or KUDOS) 
Sponsor: NIH (1R01 HD047315) 
INTRODUCTION 
As a pregnant woman who is between 8 and 20 weeks of gestation, you are being 
invited to enroll in a research study of a nutrient (DHA) that is a component of normal 
brain and important for brain development. The centers involved in the study are the 
University of Kansas Medical Center in Kansas City, Kansas, St. Luke’s Hospital in 
Kansas City, Missouri, and Truman Medical Center in Kansas City, Missouri. If you 
decide to enroll in this study, your baby will participate in research procedures at the 
University of Kansas Medical Center. Dr. Susan Carlson is the main investigator for this 
study. A total of 350 pregnant women will be enrolled in this study between October 
2005 and January 2010. 
You do not have to participate in this research study. It is important that before you 
make a decision to participate, you read the rest of this form. You should ask as many 
questions as you need to understand what will happen if you participate in the study. 
BACKGROUND 
Docosahexaenoic acid (DHA) is a fat that is found in very large amounts in the brain. 
DHA is important for how my baby sees and learns. Breast milk and, since 2002, US 
formulas contain DHA. Many studies have shown that DHA in the diet helps the baby’s 
vision, attention, and ability to learn. In this way, DHA is considered an important 
nutrient for babies after they are born. 
DHA may also be important before babies are born. Four studies found that women’s 
DHA during pregnancy was related to higher infant/child function. These studies are 
called observational studies, meaning that the women’s normal DHA status was studied 
in relation to development of the baby/child. There is only one study that gave women 
DHA during pregnancy and measured development of their babies/children. That study 
showed higher IQ at 4 years of age in children whose mothers took fish oil capsules 
during the last 6 months of pregnancy. (Fish oil contains a lot of DHA). However, 
because women in the study also consumed DHA while they were breastfeeding they 
provided more DHA to their babies after they were born. Therefore, the study does not 
prove that giving DHA before babies are born will help their development. There are no 
studies that have varied DHA intake only during pregnancy. You and your child are 
being asked to participate in such an experimental study. 
PURPOSE 
The purpose of this study is to determine if a dietary supplement of DHA during 
pregnancy will help babies be born at the right time and help their development. If you 
decide to be in the study, you will have a 50-50 chance of receiving capsules with the 
supplement of DHA or ordinary food oil, which does not contain any DHA. 
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PROCEDURES 
If you choose to enroll yourself and your infant in this study, the investigators will record 
some information from your medical record about your pregnancy and medical history. 
They will also ask you a few questions about foods that you usually eat. You will have a 
blood sample collected from a vein in your arm. One-half teaspoon of blood will be 
drawn. The blood will be used to measure DHA in your blood as well as other nutrients. 
You will be asked to provide a current address and phone number where you can be 
contacted. . 
During pregnancy: You will be randomly assigned (like flipping a coin) to capsules with 
DHA-oil or ordinary food oil (which does not contain any DHA). The DHA-oil is the same 
oil that is used in US infant formulas and has been fed safely to millions of infants. 
You will be given enough capsules each month to take 3 capsules each day and you 
agree to try to consume all 3 capsules. If you consume all 3 capsules, you will consume 
600 mg of DHA. The capsules are relatively small and you should find them easier to 
swallow than many nutrient supplements. They are orange-flavored, so if you burp 
(common in pregnancy and in the first week of taking any nutrient supplement), the 
taste should not be unpleasant. You do not need to take the capsules at any specific 
time as they are a nutrient and not a drug. However, you should decide upon a regular 
time to take them so that taking the capsules will become a habit and you won’t forget. 
For example, you might wish to take them just before you go to bed or when you have 
your first beverage of the day. 
Neither you nor the investigators will know which capsules you have been assigned to. 
On the day you enroll for the study, we will send you home with your first bottle of 
capsules. About 30 days later (early enough so that you do not run out of capsule), you 
will receive another bottle of capsules in the mail. AT THAT TIME, YOU AGREE TO 
PLACE THE FIRST BOTTLE WITH ANY REMAINING CAPSULES IN THE ENVELOPE 
AND DROP IT INTO THE MAIL. 
This process will be repeated each month until your baby is born and you will continue 
to take 3 capsules per day until your baby is born. Each time you receive a new bottle, 
you will mail back the bottle that you have been using and that day will open and begin 
using the new bottle. 
The investigators will contact you by phone at least once per month. They will ask about 
capsule intake and they will ask how you are doing. Maintaining contact with our study 
personnel on a monthly basis is very important. 
IF YOUR PHONE NUMBER OR ADDRESS CHANGES AT ANY TIME DURING THE 
STUDY, YOU WILL LET THE INVESTIGATORS KNOW BY CALLING 913-588-3781 
AND LEAVING A MESSAGE. 
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Delivery: After you are admitted to the hospital to deliver, you should telephone study 
personnel or ask the person at admitting to telephone them. You will be given a cell 
phone number today to call. Once you deliver your baby, the investigators will visit you 
in the hospital to collect data about your delivery and your baby’s health. A sample of 
your baby’s cord blood will be collected after delivery by nurses at the hospital and 
given to the investigators. A nurse will also draw a small blood sample (one-half 
teaspoon) from you while you are in the hospital. The blood samples will be used to 
measure DHA and other nutrients. The investigators will visit you, and give you an 
appointment for your baby’s first follow-up visit at KUMC. 
Visit 1 (6 weeks of age): The investigators will measure how your baby sees using a 
test that involves placing 3 electrodes directly on your baby’s head. The process 
involves cleaning the area then placing a small amount of paste similar to toothpaste on 
the head. The electrodes are placed on top of the paste. The electrodes will be used to 
record your baby’s brain waves while he/she is looking at pictures. Your child’s weight, 
height and head circumference will be measured again and you will be asked questions 
about what your baby eats. If you are breastfeeding your baby, you will be asked to 
provide a teaspoon of breast milk to the investigator. The sample will be frozen and 
analyzed for fats that are found in the capsules. The visit should last about 40 minutes. 
You should arrive on time and allow that amount of time for the visit. 
Visit 2 (4 months of age): The investigators will measure how your baby sees using 
the same test as before and another vision test. Your baby will wear a pair of plastic 
glasses during the second test. In another test, your child will be given an object to look 
at several times. The investigator will measure how long he/she looks at the object and 
how quickly he/she stops looking at the object. Your child will be video recorded during 
the test. Your baby’s heart rate will be measured during the test. Your baby’s height, 
weight and head circumference will be measured and you will be asked about what food 
your baby eats. Your baby will have a blood sample collected by either heel stick or 
drawn from a vein. If it is necessary to use a heel stick, the investigator may use a 
cream or spray that will numb the area before obtaining the sample. One-half teaspoon 
of blood will be drawn. The blood will be used to measure DHA and other nutrients. You 
should let the investigator know if your baby has been sick or not acting well since 
his/her last visit. The visit will take 60-90 minutes. 
Visit 3 (6 months of age): The investigators will measure how your baby sees using 
the test that requires him/her to wear a pair of plastic glasses. In another test, he/she 
will be given an object to look at several times (just like at 4 months of age). The 
investigator will measure how long he/she looks at the object and how quickly he/she 
stops looking at the object. Your child will be video recorded during the test. Your baby’s 
heart rate will be measured during the test. Your baby’s height, weight and head 
circumference will be measured. You will be asked questions about what your baby 
eats. You should let the investigator know if your baby has been sick or not acting well 
since his/her last visit. The visit should take 40 -60 minutes. 
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Visit 4 (9 months of age): Your baby will have both tests that measure how he/she 
sees. In another test, your child will be given an object to look at several times (just like 
at 4 and 6 months of age). The investigator will measure how long he/she looks at the 
object and how quickly he/she stops looking at the object and your baby’s heart rate will 
be measured during the test. Your child will be video recorded during the test. Your 
baby’s height, weight and head circumference will be measured. You will be asked 
questions about what your baby eats. You should let the investigator know if your baby 
has been sick or not acting well since his/her last visit. The visit should take about 40-60 
minutes. 
Visit 5 (10 months of age): During this visit your baby will be placed on your lap in 
front of a small table. A test will be completed with a small toy, foam block and 2 cloths 
that will be placed in front of your child. You will also take a short language test. The 
small toy will be given to your child to keep. In another test, your baby will be asked to 
take turns with the researcher building fun toys. After your baby has played for a 
moment with the pieces, the researcher will show him or her how to build the toy. Then, 
your baby will be given a turn to put the toy together. Your baby’s turn will happen either 
immediately or after 10-minutes of play with other things. Your child will be video 
recorded during the tests. You should let the investigator know if your baby has been 
sick or not acting well since his/her last visit. You will be asked questions about what 
your baby eats. The entire 10-month visit should last 65 - 70 minutes. 
Visit 6 (12 months of age): The investigators will measure how your baby sees using 
both vision tests. Your child will be video recorded while playing with an interesting toy 
and the investigator will use the recording to measure some aspects of attention. Your 
child’s height, weight and head circumference will be measured. You will be asked 
questions about what your baby eats. You should let the investigator know if your child 
has been sick or not acting well since his/her last visit. The visit should take about 2 
hours. It is important that your child be rested before the testing at this visit. If for some 
reason your baby cannot finish the tests that day – this may happen if he/she is 
unusually fussy or tired – you will be asked to return to finish the remaining tests within 
7 days. 
Visit 7 (18 months of age): The investigators will measure how your child sees using 
the test that he/she had while wearing plastic glasses. Your child will be video recorded 
while playing with an interesting toy and the investigator will use the recording to 
measure some aspects of attention. Your child will also be given a standardized test to 
measure mental and physical development. Your child’s height, weight and head 
circumference will be measured. You will be asked questions about what your baby 
eats. You will be asked questions about the words your child uses and understands. 
You should let the investigator know if your child has been sick or not acting well since 
his/her last visit. The visit should take about 2 hours. It is important that your child be 
rested before the testing at this visit. If for some reason your child cannot finish the tests 
that day – this may happen if he/she is unusually fussy or tired – you will be asked to 
return to finish the remaining tests within 7 days. 
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RISKS 
Some redness, soreness, or bruising may occur at the site of blood sampling. There is 
also a very slight risk of infection. 
You may experience burping from the capsules and find this unpleasant 
There are no known risks of consuming the amount of DHA you will be provided if you 
receive the DHA. Even if you forget to take your capsules for one or two days, there is 
no known risk of deciding to “catch up” on the third day. The amount is smaller than 
pregnant women in many countries eat every day. Nevertheless, you could develop a 
problem that has not been observed before. 
NEW FINDINGS STATEMENT 
You will be informed if any significant new findings develop during the course of the 
study that may affect your willingness to participate or to allow your child to participate 
in this study. 
BENEFITS 
You and your child may or may not benefit from participating in this study. If you receive 
the supplement, it may help your baby to be born at the right time and your 
baby’s/child’s development. If you will not get the supplement, your baby and you will 
not be getting any of those benefits. It is also possible that all infants/children will get 
some benefit from being followed closely with developmental testing. It is hoped that 
additional information gained in this research study may be useful in understanding if 
DHA can help your baby be born at the right time and help your baby’s vision, attention, 
and learning as he or she grows. You will receive a video recording of your infant doing 
the 4, 6, and 9 month looking test when the 12 month visit is complete. 
ALTERNATIVES 
You do not have to participate in this study to be able to take DHA supplements while 
you are pregnant. You may purchase capsules containing DHA at local stores without a 
prescription (for example, Osco, Costco, Wal-Mart). There are also several brands of 
prenatal supplements with DHA available by prescription or over the counter. The 
prenatal capsules typically contain 200 mg of DHA each and are marketed to take one 
capsule/day as a DHA supplement. 
COSTS 
Capsules containing either DHA or food oil will be provided to you at no cost while you 
are participating in this study. You will not incur any costs because of your or your 
child’s participation 
PAYMENT TO SUBJECTS 
If study investigators are able to communicate with you each month you will be given 2 
bonus gift cards to either Wal-Mart or Target of $25 each. The first gift card will be given 
to you half way through your treatment phase if communication is maintained at least 
one time each month during the first half of your treatment. The second gift card will be 
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given at delivery if communication maintained at least one time each month during the 
second half of your treatment. 
Additionally, if the study investigators are called after you are admitted for delivery you 
will be given your choice of a bonus gift card worth $50 from either Wal-Mart or Target. 
You may make the call yourself or have someone else call for you. Study personnel will 
give you the gift card when they come to the hospital after your baby is born. 
Once your baby is born, you will receive a check for $50 after your baby completes 
each of the following visits: 6 weeks, 4 months, 6 months, 9 months, and 10 months. 
You will receive a check for $100 after your child completes each of the following visits: 
12 and 18 months. The reimbursements are to cover the costs of transportation and to 
partially compensate you for your time required to participate in the study. 
Your name, address, social security number, and the title of this study will be given to 
the KUMC Research Institute. This is done so that the Research Institute can write a 
check for study payments. Payments are taxable income. 
IN THE EVENT OF INJURY 
In the event you experience any serious health problem (hospitalization, life-threatening 
illness, or death) for any reason during your pregnancy, you should immediately seek 
treatment or help in the way you normally would as if you were not in a study. You 
should let Susan Carlson, Ph.D. know about any of these problems as soon as possible 
by calling her office (913-588-5359) or the study office (913-588-3781). A message may 
be left at both numbers. Dr. Carlson may also be reached at home (816-960-1805). 
INSTITUTIONAL DISCLAIMER STATEMENT 
If you believe you have been injured as a result of participating in research at Kansas 
University Medical Center (KUMC), you should contact the Director, Human Research 
Protection Program, Mail Stop #1032, University of Kansas Medical Center, 3901 
Rainbow Blvd., Kansas City, KS 66160. Compensation to persons who are injured as a 
result of participating in research at KUMC may be available, under certain conditions, 
as determined by state law or the Kansas Tort Claims Act. 
Truman Medical Center (TMC) will provide medical attention to you if you suffer any 
injury or harm as a direct result of participating in this research project. TMC, your study 
doctor, and the sponsor of this study will decide, at their discretion, who should pay for 
the medical care. TMC will provide treatment to you in the event of any medical 
emergency while present at TMC, whatever the cause. Moreover, you will have the 
benefit of the coverage of any existing healthy insurance you own. Participation in this 
research study does not take the place of routine physical examinations or clinic visits to 
your person physician. If you believe you have been injured as a result of participating 
in this study you are encouraged to contact the study investigator, Dr. Susan Carlson, at 
her work number, 913-588-5359. 
The University of Missouri-Kansas City appreciates the participation of people who help 
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it carry out its function of developing knowledge through research. Although it is not the 
University’s policy to compensate or provide medical treatment for persons who 
participate in studies, if you think you have been injured as a result of participating in 
this study, please call the investigator, Dr. Susan Carlson at 913-588-5359 (work) or 
Sheila Anderman, IRB administrator of UMKC’s Adult Health Sciences Institutional 
Review Board at 816-235-6150 
CONFIDENTIALITY AND PRIVACY AUTHORIZATION 
Names of subjects or information identifying subjects will not be released without written 
permission unless required by law. Videotapes of your baby when he/she is looking at 
pictures and playing with toys will be used only by the investigators and their students 
and to make a videotape copy for you. The videotapes will be secured under lock and 
key like all other information that could be linked directly to your child. The videotape of 
your child will not be shown without specific permission from you and even then would 
not identify your child by name. Efforts will be made to keep you and your child’s 
personal information confidential. Researchers cannot guarantee absolute 
confidentiality. If the results of this study are published or presented in public, 
information that identifies you and/or your baby will be removed. 
The privacy of you and your child’s health information is protected by a federal law 
known as the Health Insurance Portability and Accountability Act (HIPAA). If you choose 
to participate in this study, you will be asked to give permission for researchers to use 
and disclose your and your baby’s health information that is relevant to the study. 
To perform this study, researchers will collect health information about me and my child 
from his/her and my medical records and from the study activities that are listed in the 
Procedures section of this consent form. My and my baby’s study-related health 
information will be used at KU Medical Center by Dr. Carlson, members of the research 
team, Truman Medical Center, St. Luke’s Hospital and the KU Hospital Medical Record 
Department. The KUMC Research Institute as well as officials at Truman Medical 
Center and St. Luke’s Hospital that oversee research, including the KUMC Human 
Subjects Committee, the IRB that governs Truman Medical Center and St. Luke’s 
Hospital and other committees and offices that review and monitor research studies, 
may also see my and my baby’s study-related health information. 
Dr. Carlson and her team may share information about me and my baby with 
representatives of Martek Biosciences, the monitoring company who verifies study data, 
the laboratory that processes study lab samples, other business partners who help with 
the study, the U.S. Food and Drug Administration (FDA), and U.S. agencies that govern 
human research (if and when regulatory compliance issues arise). Martek Biosciences 
(Columbia, MD) donated the capsules for this study that is otherwise supported by the 
National Institute of Child Health and Human Development. 
Some of the persons or groups that receive my and my baby’s study information may 
not be required to comply with HIPAA privacy laws. My and my child’s information may 
lose its federal protection if those persons or groups disclose it. 
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Permission granted on this date to use and disclose my health information remains in 
effect indefinitely. By signing this form I give permission for the use and disclosure of my 
and my child’s information for purposes of the study at any time in the future. 
If I enroll in the study, the investigators cannot tell me what capsule I was assigned to 
until the study ends. This may be after I have stopped taking the capsules. 
QUESTIONS 
I have read the information in this form. Dr. Carlson or her associates have answered 
my question(s) to my sati,action. I know if I have any more questions after signing this I 
may contact Dr. Carlson or one of her associates at (913) 588-5359. If I have any 
questions about my or my child’s rights as a research subject, I may call (913) 588-1240 
or write the Human Subjects Committee, University of Kansas Medical Center, 3901 
Rainbow Blvd. MSN 1032, Kansas City, KS 66160. 
SUBJECT RIGHTS AND WITHDRAWAL FROM THE STUDY 
My and my child’s participation in this study is voluntary and the choice to not participate 
or to quit at any time can be made without penalty or loss of benefits. Not participating 
or quitting will have no effect upon the medical care of treatment my child receives now 
or in the future at the University of Kansas Medical center. The entire study may be 
discontinued for any reason without my consent by the investigator conducting the 
study, by the sponsor of the study, or the FDA. My child’s participation can be 
discontinued by the investigator or by the sponsor if it is felt to be in my child’s best 
interest or if I do not follow the study requirements. If I choose to withdraw before my 
child is 18 months of age, I may be asked to answer questions about the study on the 
telephone. 
If I want to cancel permission to use my or my child’s health information, I should send a 
written request to Dr. Carlson. The mailing address is Susan Carlson, Ph.D., Dept. of 
Dietetics and Nutrition, MS 4013, 4019 Delp, University of Kansas Medical Center, 3901 
Rainbow Boulevard, Kansas City, KS 66160. If I cancel permission to use my child’s 
health information, the research team will stop collecting any additional information 
about me and my child. 
Should the study be terminated prior to the completion of my pregnancy, neither the 
investigator nor the University of Kansas Medical Center will be under any obligation to 
provide me with DHA capsules used in the study. 
CONSENT 
Dr. Carlson or her associates have given me information about this research study. 
They have explained what will be done and how long it will take. They explained the 
inconvenience, discomfort and risks that may be experienced during this study. 
By signing this form, I give my permission for my and my child’s health information to be 
used and disclosed for the purposes of this research study. If I choose not to sign this 
form, my child and I will not be able to participate in the study. 
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I voluntarily consent to my and my child’s participation in this research study. I have 
read the information in this form and have had an opportunity to ask questions and have 
them answered. I will be given a copy of the signed form to keep for my records. 
___________________________________  
Type/Print Subject's Name  
____________________________________       _______           __________________ 
Signature of Subject        Time     Date 
____________________________________  
Type/Print Name of Person Obtaining Consent 
____________________________________           __________________ 
Signature of Person Obtaining Consent       Date 
__________________________________  
Type/Print Name of Principal Investigator  
____________________________________           __________________ 
Signature of Principle Investigator      Date 
 
May the investigators contact you after the study is over to ask if you interested in 
continuing your child’s participation? If you agree to be contacted, the investigators 
would explain any new study to you later and you would have the chance to decide if 
you wanted to participate at that time (please circle your response). 
Yes  
No 
____________________________________  
Type/Print Subject's Name  
____________________________________       _______           __________________ 
Signature of Subject        Time     Date 
____________________________________  
Type/Print Name of Person Obtaining Consent 
____________________________________           __________________ 
Signature of Person Obtaining Consent       Date 
____________________________________  
Type/Print Name of Principal Investigator  
____________________________________           __________________ 
Signature of Principle Investigator      Date 
 
